There have been various studies conducted so far in order to calculate the effects of statins in reducing cardiovascular events and slowing the progression of coronary atherosclerosis, the significant cardiovascular risk remains. icosapent ethyl, a highly purified acid, plays a very pivotal role in controlling the infections of the person in the best possible manner. The EVAPORATE trial sought to determine whether IPE 4g/ day, as an adjunct to diet and statin therapy, would result in a greater change from baseline in plaque volume. This has to be measured with the help of multidetector tomography. Therefore, for the purpose of this study, a total of 80 patients were taken so far. These people were the ones who were already infected by the diseases in the best possible manner. The results concluded that the icosapent ethyl demonstrated significant regression of LAP volume on MDCT compared with the placebo over the 18 months and was able to yield the positive results in the best possible manner.
August 6, 2020
November 6, 2017
November 1, 2011
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.